A trial update dated September 1, 2026 reports that a study titled "Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE" is currently recruiting. The study is registered under identifier NCT06679881 and is listed as Phase 3.
This trial evaluates an oral extended-release tablet formulation of deucrictibant for long-term, open-label use in adolescents and adults with hereditary angioedema (HAE), specifically for prophylaxis against angioedema attacks. The study status is recorded as recruiting, meaning participant enrollment is ongoing.
No results, efficacy data, or safety findings have been posted for this trial at this time. The event data available only confirms the trial's title, phase, recruiting status, and registration date. No outcomes should be inferred from this update.
Bradykinin is relevant to hereditary angioedema research given its role in vascular permeability and swelling associated with the condition. This compound remains classified as unapproved for research use.
Readers interested in background on bradykinin can consult the compound overview for further context.